A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCRaß+ CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)

Gender
Any

Age Group
Any

At a Glance

IRB#CIRB20-0689

Lead PhysicianJames L. LaBelle

Collaborator(s)N/A

EligibilityRecruiting